

UV Rays Leading to Xeroderma Pigmentosum

K Anuja*

Department of Chemistry, Andhra University, Andhra Pradesh, India

Commentary

Received: 14/09/2016
Accepted: 25/09/2016
Published: 30/09/2016

*For Correspondence

K Anuja, B Pharma, Andhra University, Andhra Pradesh, India, Tel: 8984835657.

E-mail: kanujroc@rediffmail.com

Keywords: Xeroderma pigmentosum, DNA, Tumor, Skin, Cancer.

ABSTRACT

Xeroderma pigmentosum is an acquired condition described by a compelling affectability to bright (UV) beams from daylight. This condition for the most part influences the eyes and ranges of skin presented to the sun. Xeroderma pigmentosum is an uncommon issue transmitted in an autosomal latent way. It is portrayed by photosensitivity, pigmentary changes, untimely skin maturing and harmful tumour improvement. These signs are because of a cell extreme touchiness to bright (UV) radiation coming about because of a deformity in DNA repair. Strikingly, patients with this issue, trichothiodystrophy have surrenders in a portion of the same qualities as XP however they have essential formative anomalies without an expansion in skin growth.

INTRODUCTION

Xeroderma pigmentosum is an autosomally latent acquired malady, which implies that you have acquired two passive xeroderma pigmentosum genes. Patients are inclined to threatening skin neoplasms in the face, neck and upper trunk, the tip of the tongue, and the foremost eye surfaces. Visual ailment is apparent in no less than 40% of XP patients and frequently causes visual weakness ^[1]. Clinically obvious visual illness incorporates eyelid decay and tumors, corneal sicca and opacification, presentation keratitis, pterygium and endless conjunctival infusion. Portraying complementation bunches indicated the significance of various basic qualities. Concentrating on contrasts in disease period of onset and hidden atomic marks in tumors happening either in XP patients or the all-inclusive community has prompted bits of knowledge into contrasts in cancer-causing components ^[2-10].

The signs and side effects of xeroderma pigmentosum are an aftereffect of a disabled DNA repair framework. In individuals who don't have xeroderma pigmentosum, cell harm from UV light is retouched by the DNA repair framework ^[11,12]. Proceeded with sun introduction will prompt the second stage, which is described by poikiloderma. This is the place there are unpredictable patches of helped or obscured skin, a bug catching network like gathering of blood spots and vessels are seen through the skin, and there is diminishing of the skin ^[13-20]. Epidemiologic ponders in the typical populace have been utilized as confirmation to bolster a part for daylight as a reason for skin cancer. Cockayne Disorder (CS), another uncommon neurodegenerative issue, consequently she was the primary patient with the XP/CS complex ^[21-24]. The DNA repair rate was diminished in 12 of the patients and typical in one patient (XP4BE), the main XP variant. The normal skin growths, basal cell carcinoma, squamous cell carcinoma, and melanoma, happen essentially all the more frequently in individuals with xeroderma pigmentosum. The watched number of NMSC was contrasted with the normal number from the Kaiser Permanente skin growth database after modification for age, sex, race and birth partner ^[10,24-30]. The watched number of melanoma skin malignancies was contrasted and the normal number in the all-inclusive community (O/E proportion) in light of the NCI Observation, The study of disease transmission and Final products (Soothsayer) tumor database ^[31-40].

This condition is acquired in an autosomal latent example, which implies both duplicates of the quality in every cell have changes. The guardians of a person with an autosomal latent condition every convey one duplicate of the transformed quality; however they commonly don't give suggestions and side effects of the condition ^[41-60]. The sub-atomic deformities in XP cells result in a significantly raised acceptance of transformations in sun-uncovered skin of influenced people. This expanded transformation recurrence likely records for the pigmentation changes and the skin growths. Xeroderma pigmentosum can for the most part be convincingly analyzed by measuring the DNA repair component from skin or blood samples ^[61-70]. Actinic keratoses might be dealt with by cryotherapy or 5-fluorouracil cream. This is a vitamin A subordinate that may avert development of new tumors. The

DNA harm is aggregate and irreversible early finding and broad sun security can possibly avert skin diseases in XP patients and delay their life expectancy [71-85]. Eye care comprises of shades, simulated tears, steroid drops and tasteless balm during the evening. These are key segments of a counteractive action program XP related cutaneous, visual and oral injuries and scatters ought to be dealt with as in whatever other individual by Oral Retinoids, topical treatment and potential treatments or by chemical Photolyase [86-99].

REFERENCES

1. Moschos MM, et al. Evaluation of the emotional status in patients with retinitis pigmentosa using phq-9 and zung scores: Is the depression common in retinitis pigmentosa? J Clin Exp Ophthalmol. 2016;7:593.
2. Chow EPY, et al. The effect of dietary carotenoids of different forms: Microemulsified and non-microemulsified on the growth performance, pigmentation and hematological parameters in hybrid catfish. J Aquac Res Development. 2016;7:437.
3. Christaki E, et al. Phycobiliproteins: A new perspective in natural pigments derived from microalgae. J Oceanogr Mar Res. 2016;4:e114.
4. Park EJ, et al. Induction of activating transcription factor 6 via activation of ERK and ROS-P38 MAPK is related to methylglyoxal-induced cytotoxicity in human retinal pigment epithelial cells. Biochem Pharmacol (Los Angel). 2016;5:214.
5. Yi Hao Y, et al. miR-146a is upregulated during retinal pigment epithelium (RPE)/choroid aging in mice and represses IL-6 and VEGF-A expression in RPE cells. J Clin Exp Ophthalmol. 2016;7:562.
6. Lim EWL, et al. Conjunctival dysplasia and atypical secondary acquired melanosis in xeroderma pigmentosum. J Cytol Histol.
7. Venkiteswaran K, et al. Commentary on - Human embryonic retinal pigment epithelial (rpe) cell transplants for chronic refractory cocaine addiction. Health Care: Current Reviews. 2016;4:165.
8. Eriksen NT. Research trends in the dominating microalgal pigments, β -carotene, astaxanthin and phycocyanin used in feed, in foods and in health applications. J Nutr Food Sci. 2016;6:507.
9. Maiti R, et al. Biodiversity in leaf chemistry (pigments, epicuticular wax and leaf nutrients) in woody plant species in north-eastern Mexico, a synthesis. Forest Res. 2016;5:170.
10. Cagalli A, et al. Pigmented papules and patches of the folds: A case series of Icthen planus pigmentosus inversus with review of the literature. J Clin Case Rep. 2016;6:732.
11. Li T, et al. Effects of different carotenoids on pigmentation of blood parrot (*Cichlasoma synspilum* \times *Cichlasoma citrinellum*). J Aquac Res Development. 2016;7:414.
12. Vijay K, et al. Colourful side of bacteriology: The pigmented bacteria. Adv Genet Eng. 2016;5:i104.
13. Muzamil L, et al. Scleral and body hyperpigmentation in disseminated tuberculosis with adrenal insufficiency (Addison's disease). J Gen Pract. 2016;4:i002.
14. Marine B, et al. CCN3 and CCN5, New factors associated with skin pigmentation. Pigmentary Disorders. 2016;2:239.
15. Sharma REK and Sharma RK. Generalized pigmented lupus erythematosus-A new clinical subset? Pigmentary Disorders. 2016;2:237.
16. Satyajit P (2016) Overview of xerodermatic pigmentum mutations, prognosis and treatment. Adv Genet Eng. 2016;5:141.
17. Keleştemur GT and Çoban OE. Effects of the β -carotene on the growth performance and skin pigmentation of rainbow trout. J Fisheries Livest Prod. 2016;4:164.
18. Çerman AA and Altuna IK. Oral pigmentation. Pigmentary Disorders. 2016;2:234.
19. Sheha MA, et al. Pigmented skin lesion diagnosis by automated imaging system. J Bioengineer & Biomedical Sci. 2015;6:170.
20. Hasan S and Saeed S. Xeroderma pigmentosum-A rare genodermatosis: Overview of literature. Pigmentary Disorders. 2015;2:230.
21. Chang YJ, et al. Autophagic regulation of retinal pigment epithelium homeostasis. Pigmentary Disorders. 2015;2:227.
22. Thota P, et al. Omeprazole induced skin hyperpigmentation. RRJHCP
23. Sarma M, et al. Incidental detection of pigmented villonodular synovitis by 18FDG PETCT imaging in a case of poorly differentiated thyroid carcinoma. J Nucl Med Radiat Ther. 2015;6:267.
24. Patil S, et al. Pigmentary disorders of oral mucosa. Pigmentary Disorders. 2015;2:225.

25. Ali SA, et al. Melanogenesis: Key role of bioactive compounds in the treatment of hyperpigmentary disorders. *Pigmentary Disorders*. 2015;2:223.
26. Jing Y. Retinitis pigmentosa research in the era of precision medicine: Discovery to translation. *J Clin Exp Ophthalmol*. 2015;6:e115.
27. Nordlund JJ. Hyperpigmentation: Its historical treatment and the development of hydroquinone. *Pigmentary Disorders*. 2015.2:221.
28. Al-Khouja M and Corrigan PW. The stigma of pigmentary disorders. *Pigmentary Disorders*. 2015;2:217.
29. Khanna U and Khandpur S. Pigmented contact dermatitis. *Pigmentary Disorders*. 2015;2:214.
30. Cayir RIEA. A rare cause of pigmentation disorder: Tuberous sclerosis complex. *Pigmentary Disorders*. 2015;2:211.
31. Hernandez IR and Sarmiento RG. DNA repair polymorphisms in glioblastoma susceptibility. *J Cancer Clin Trials*. 2016.
32. Pinheiro DML, et al. Polymorphisms in DNA repair gene XRCC1 (Arg194Trp) and (Arg399Gln) and their role in the susceptibility of bacterial meningitis. *J Meningitis*. 2016;1:105.
33. Jarrett SG and D'Orazio JA. Cutaneous hormonal controls of melanocyte DNA repair through camp signaling. *J Carcinog Mutagen*. 2015;6:e116.
34. de Sousa JF and Valente V. DNA damage response and DNA repair genes in cancer progression: Good or bad guys? *Brain Disord Ther*. 2015;S2-S4.
35. Schanz S, et al. Genetically-defined DNA repair capacity determines the extent of DNA damage accumulation in healthy mouse tissues after very low doses of ionizing radiation. *J Carcinog Mutagen*. 2014;5:196.
36. Vageli DP, et al. Mismatch DNA repair hMSH2, hMLH1, hMSH6 and hPMS2 mRNA expression profiles in colorectal carcinomas. *J Genet Syndr Gene Ther*. 2013;4:191.
37. St-Laurent Pedneault C. Regulated expression of a FANCL splicing variant as a potential modifier of DNA repairs activity. *J Genet Syndr Gene Ther*. 2013;4:143.
38. Bélanger S. Impaired effects of a FANCC splicing isoform in FANCC-BRCA DNA repair pathway. *J Genet Syndr Gene Ther*. 2013;4:144.
39. Makiko ONO. Influence of self-stimulation of the parasympathetic nervous system on lymphocyte function and DNA repair function in family caregivers. *J Nurs Care*. 2013;2:127.
40. Asimuddin M and Jamil K. Insight into the DNA repair mechanism operating during cell cycle checkpoints in eukaryotic cells. *Biology and Medicine*. 2012;4:173.
41. Liu L. The role of nitric oxide in cancer cell DNA repair, hypoxia adaptation and drug resistance. *Single Cell Biol*. 2013;2:103.
42. Kanungo J. DNA repair defects and DNA-PK in neurodegeneration. *Cell Dev Biol*. 2012;1:e105.
43. Hirano T and Tamae K. Differentiation of embryonic stem cells and oxidative DNA damage/DNA repair systems. *J Stem Cell Res Ther*. 2012:S10-005.
44. Abdel-Hafiz HA. Role of Hepatitis B virus X protein in DNA repair during hepatocellular carcinoma development. *J Carcinog Mutagen*. 2014;S3-001.
45. Emery IF, et al. Assessment of DNA repair mechanisms to determine the susceptibility of non-small cell lung cancer to alkylating agents. *J Cancer Sci Ther*. 2011;3:92-95.
46. Makhoul E, et al. Primary gallbladder and rectal neoplasms: rare synchronous digestive tumors. *J Gastrointest Dig Syst*. 2016;6:435.
47. Michiels JJ. Signs and symptoms of myeloproliferative neoplasms (MPN), quality of life, social activity, work participation and the impact of fatigue in Dutch MPN patients: A one country questionnaire investigation of 497 MPN patients. *J Hematol Thrombo Dis*. 2016;4:241.
48. Michiels JJ, et al. Secondary myelofibrosis in the naturel history of JAK2, MPL and CALR mutated myeloproliferative neoplasms. *J Hematol Thrombo Dis*. 2016;4:238.
49. Testa U, et al. IL-3 Receptor alpha chain is a biomarker and a therapeutic target of myeloid neoplasms. *J Mol Biomark Diagn*. 2016;7:274.
50. Qi CF, et al. TMEM4 is highly expressed in plasma cell neoplasms and associated with B lymphocyte differentiation. *Immunol Disord Immunother*. 2016;1:102.
51. Kamiguchi IE, et al. Mammary neoplasms in female dogs: Identification of cytopathological criteria for malignancy. *J Cytol Histol*. 2016;7:392.

52. Hançerlioğullari O, et al. Our three year clinical experience at appendiceal incidental neoplasms and management of appendicial tumors. *J Clin Exp Pathol*. 2015;5:260.
53. Agarwal A, et al. Benign endobronchial neoplasms: A Review. *J Pulm Respir Med*. 2015;5:275.
54. Kimura W and Tezuka K. Acute pancreatitis is a predictive factor for malignancy in mixed or main duct intraductal papillary mucinous neoplasms. *Pancreat Disord Ther*. 2015;5:148.
55. Moore CR, et al. Targeting TRAF3 downstream signaling pathways in B cell neoplasms. *J Cancer Sci Ther*. 2015;7:67-74.
56. Michiels JJ, et al. The 2006 2008 European clinical, molecular and pathobiological (2008 ECMP) classification and the 2007 WHO revised criteria for myeloproliferative neoplasms. *J Hematol Thrombo Dis*. 2015;3:190.
57. Wang Xi, et al. Myeloid neoplasms associated with t(3;12)(q26.2;P13) are clinically aggressive and frequently harbor FLT3 mutations: A report of 8 cases and review of literature. *J Leuk*. 2014;2:161.
58. Michiels JJ, et al. WHO clinical molecular and pathological (WHO-CMP) diagnostic criteria for the classification and staging of five distinct JAK2, MPL and CALR mutated myeloproliferative neoplasms. *J Hematol Thrombo Dis*. 2014;2:172.
59. Poruk KE, et al. Solid pseudopapillary neoplasms of the pancreas: A review. *Pancreat Disord Ther*. 2014;4:2.
60. Luo B. The emerging role of the hematopoietic stem cell niche in myeloproliferative neoplasms. *J Mol Genet Med*. 2014;8:133.
61. Ghannam DM, et al. CD26 expression in mature B-cell neoplasms and its prognostic impact on B-cell chronic lymphocytic leukemia. *J Blood Disord Transfus*. 2014;5:222.
62. Goh BKP. Current guidelines for the management of branch duct intraductal papillary mucinous neoplasms. *Pancreat Disord Ther*. 2014;4:1.
63. Gazis A, et al. Bipolar radiofrequency ablation of spinal neoplasms: Average power to be the most predictive value in respect of induced extent of ablation volume. *J Spine*. 2014;3:164.
64. Lima M. Aggressive mature natural killer cell neoplasms: From EBV-Infection to disease etiopathogeny. *J Blood Disord Transfus*. 2014;5:193.
65. Lima M. Aggressive mature natural killer cell neoplasms: From disease biology to disease manifestations. *J Blood Disord Transfus*. 2014; 5:182.
66. Bock O. The current molecular site of the myeloproliferative neoplasms - TET- \hat{A} - \hat{A} te with the JAKpot but no LNK so far to Resolve Complexity. *J Leuk*. 2013;1:108.
67. Robak T. New kinase inhibitors for the treatment of chronic hematological neoplasms-editorial. *J Dev Drugs*. 2012;1:e114.
68. Simona MGS and Caius SC. Onychodystrophy and scarring alopecia in epidermolysis bullosa acquisita: A case based review of the literature. *J Clin Case Rep*. 2016;6:709.
69. Venkataram and George EP. Treatment of posttraumatic scar with ablative fractional erbium: YAG Laser. *Cosmetol & Oro Facial Surg*. 2016;2:1.
70. Alsharif S. Laptop computer induced erythema ab igne: A systematic review of case reports. *J Clin Exp Dermatol Res*. 2016;7:319.
71. Venkataram and George EP. Fractional ablative Er: YAG Laser: Alternative approaches to the treatment of port wine stain. *J Cosmetol & Oro Facial Surg*. 2015;1:1.
72. Ryan TJ. Community dermatology: A branch of dermatology embracing all skin carers in the restoration of skin function. *Health Care Current Reviews*. 2015;3:2.
73. Sugiura K. Prevention and treatment of skin injury and trauma in triathlon competition day. *J Sports Med Doping Stud*. 2015.
74. Atzori L, et al. Cutaneous adverse reactions during anti-TNF alpha treatment for inflammatory bowel diseases: The experience of the dermatology clinic of Cagliari. *J Pharmacovigilance*. 2015;S2.
75. Lisi R, et al. Skin toxicity after radiotherapy: About a case. *Biochem Anal Biochem*. 2015;4:195.
76. Lotti T, et al. New therapeutic opportunities in dermatology: Low dose cytokines treatment for vitiligo. *Pigmentary Disorders*. 2015;S3.
77. Arif T, et al. Therapeutic and diagnostic applications of nanotechnology in dermatology and cosmetics. *J Nanomedicine Biotherapeutic Discov*. 2015.
78. Tripathi V. Late advances and new ideas into the diversity of dermatology. *RRJMHS*. 2015.

79. Mukunthan A. A survey of applications of laser in dermatology? Medical Physics. IJRSET. 2012.
80. Lehmann AR, et al. Xeroderma pigmentosum. Otphanet J Rare Dis. 2011;6:70.
81. Mareddy S, et al. "Xeroderma pigmentosum: Man deprived of his right to light." The Scientific World Journal. 2013;3:8.
82. Hua RX, et al. Association of XPC gene polymorphisms with colorectal cancer risk in a southern Chinese population: A case-control study and meta-analysis. Genes. 2016;7:73.
83. Munford V. A genetic cluster of xeroderma pigmentosum variant patients with two different founder mutations. Br J Dermatol. 2015.
84. Koch SC, et al. Molecular mechanisms of xeroderma pigmentosum (XP) proteins. Rev Biophys. 2016;49:23-25.
85. Zhang J. et al. Lentiginous phenotypes caused by diverse pathogenic genes (SASH1 and PTPN11): Clinical and molecular discrimination. Clin Genet. 2016;90:372-377.
86. Zhou EY, et al. Clinical and molecular epidemiological study of xeroderma pigmentosum in China: A case series of 19 patients. J Dermatol. 2016.
87. Takahashi Y, et al. An XPA gene splicing mutation resulting in trace protein expression in an elderly xeroderma pigmentosum group, a patient without neurological abnormalities. Br J Dermatol. 2016.
88. Wang Y, et al. Predictive value of XPG rs2296147T>C polymorphism on clinical outcomes of cancer patients. Oncotarget. 2016;5:34-45.
89. Evans MD, et al. Nucleotide excision repair of oxidized genomic DNA is not a source of urinary 8-oxo-7,8-dihydro-2'-deoxyguanosine. Free Radical Biology and Medicine. 2016;99:385-391.
90. Nakano E, et al. The present status of xeroderma pigmentosum in Japan and a tentative severity classification scale. Exp Dermatol. 2016;25:28-33.
91. Sibar S, et al. Technical aspects and difficulties in the management of head and neck cutaneous malignancies in xeroderma pigmentosum. Arch Plast Surg. 2016;43:344-351.
92. Liu X, et al. Association between XPA gene rs1800975 polymorphism and susceptibility to lung cancer: A meta-analysis. Clin Respir J. 2016.
93. Surendra S, et al. Rare malignancies in Eastern India, socio-economic impact. Rare Tumors. 2016;8.2.
94. Gkogkolou P and Böhm M. Skin disorders in diabetes mellitus. J Dtsch Dermatol Ges. 2016;12:847-864.
95. Döbel T and Schäkel K. The role of human 6-sulfo LacNAc dendritic cells (slanDCs) in autoimmunity and tumor diseases. J Dtsch Dermatol Ges. 2016;12:874-879.
96. Dugas-Breit S, et al. Neue und altbewährte Therapieoptionen bei Mycosis fungoides und Sézary-Syndrom - eine aktuelle Bestandsaufnahme. J Dtsch Dermatol Ges. 2014;12:561-570.
97. Alter M, et al. Rückgang nicht-melanozytärer Hauttumoren nach Umstellung der Immunsuppression auf mTOR-Inhibitoren bei organtransplantierten Patienten. J Dtsch Dermatol Ges. 2015;12:480-490.
98. Schwarz M, et al. Three-dimensional multispectral optoacoustic mesoscopy reveals melanin and blood oxygenation in human skin *in vivo*. J Biophoton. 2016;9:55-60.
99. Thomas G, et al. (2015) *In vivo* nonlinear optical imaging to monitor early microscopic changes in a murine cutaneous squamous cell carcinoma model. J Biophoton. 2015;8:668-680.